It was also the second consecutive month in which the work-force grew, and the second month since last July in which the civilian labor force participation rate increased.
Late Tuesday afternoon, the companies presented mediocre trial results showing that bapineuzumab (b-mab for short) didn't work overall in an 18-month second stage trial but seemed to help a subset of patients who lack a certain gene mutation, APOE4.